Albendazole (Valbazen)

Albendazole, marketed as Valbazen by Zoetis, is a broad-spectrum benzimidazole anthelmintic approved for use in cattle and sheep, with widespread extra-label use in goats. Among the benzimidazole class of dewormers, albendazole holds a distinctive position because of its activity against liver flukes in addition to the gastrointestinal nematodes, lungworms, and tapeworms that other benzimidazoles also target. This flukicidal activity makes albendazole the only benzimidazole anthelmintic with practical utility against Fasciola hepatica in cattle and sheep in the United States, a characteristic that has sustained its relevance in livestock parasite management even as anthelmintic resistance has complicated the use of all dewormer classes.

The mechanism of action of albendazole, shared with all benzimidazole anthelmintics, involves binding to beta-tubulin in the cells of susceptible parasites, disrupting the formation of microtubules essential for cellular structure, intracellular transport, nutrient uptake, and cell division. This interference with fundamental cellular processes leads to progressive metabolic failure, cessation of egg production, and death of the parasite over a period of days following treatment. The selectivity of benzimidazoles for parasite beta-tubulin over mammalian beta-tubulin provides the therapeutic margin that makes these drugs safe for the host at recommended doses, though this selectivity is not absolute - the teratogenic effects of albendazole in early pregnancy reflect activity against rapidly dividing mammalian cells when drug exposure occurs during critical developmental windows.

Albendazole is formulated as an oral suspension at a concentration of 113.6 milligrams per milliliter, administered by oral drench using a dosing gun calibrated to deliver the correct volume based on the animal's body weight. The suspension must be shaken thoroughly before use because the active ingredient settles during storage, and inadequate mixing results in inconsistent dosing - early doses from an unmixed bottle deliver less drug than later doses, potentially leading to both treatment failures and unnecessarily high doses within the same treatment group. Oral drench administration ensures that the drug enters the rumen where absorption begins, and the rate of ruminal passage influences the duration of drug exposure and consequently the efficacy against different parasite species and stages.

The commercial availability of albendazole as an over-the-counter product for cattle and sheep makes it accessible to producers without a veterinary prescription, though responsible use requires understanding of parasite biology, resistance status, withdrawal times, and the critical reproductive safety restrictions that distinguish albendazole from other benzimidazoles. The drug's teratogenic potential in the first trimester of pregnancy is the single most important safety consideration and the primary reason that many producers and veterinarians prefer fenbendazole for routine deworming, reserving albendazole for situations where its unique flukicidal activity or broader spectrum justifies the additional management attention required to ensure reproductive safety.

The labeled indications for albendazole in cattle encompass a comprehensive range of internal parasites. Gastrointestinal nematodes susceptible to albendazole include Ostertagia ostertagi (brown stomach worm), including inhibited fourth-stage larvae, Haemonchus species (barber pole worm), Trichostrongylus species, Cooperia species, Nematodirus species, Bunostomum phlebotomum (hookworm), and Oesophagostomum radiatum (nodular worm). Activity against inhibited Ostertagia larvae is clinically significant because these arrested larvae reside within the abomasal glands in a dormant state that protects them from some other anthelmintic classes, and their synchronized emergence in spring causes Type II ostertagiasis, a severe production-limiting condition in yearling cattle. Albendazole's ability to reach these encysted larvae at labeled doses makes it a valuable tool for strategic treatment of cattle carrying inhibited larval burdens.

Lungworm activity against Dictyocaulus viviparus, the bovine lungworm, is included in the labeled indications for cattle. Lungworm infection causes verminous pneumonia characterized by coughing, labored breathing, and reduced weight gain, with severe infections capable of causing fatal respiratory failure in naive calves encountering heavy pasture contamination. Albendazole's systemic distribution following absorption from the gastrointestinal tract provides drug concentrations in pulmonary tissue sufficient to kill lungworm larvae and adults residing in the airways, though the degree of lung damage at the time of treatment influences clinical recovery.

The flukicidal activity of albendazole against Fasciola hepatica (common liver fluke) and Fascioloides magna (giant liver fluke) represents its most distinctive indication in cattle. Albendazole is effective against adult liver flukes at labeled cattle doses and has some activity against late immature stages, though it is not reliably effective against early immature flukes migrating through the liver parenchyma during the first weeks after infection. For operations in fluke-endemic areas - particularly the Gulf Coast, Pacific Northwest, Great Lakes region, and other areas with suitable snail intermediate hosts - albendazole provides a single-product approach to simultaneous nematode and fluke treatment that no other benzimidazole can match.

In sheep, the labeled spectrum includes gastrointestinal nematodes comparable to those in cattle, with the addition of species particularly important in ovine parasitology: Haemonchus contortus, Ostertagia circumcincta (now Teladorsagia circumcincta), Trichostrongylus species, Cooperia species, Nematodirus species, and Chabertia ovina. Moniezia species tapeworms are also included in the labeled indications for sheep. Fasciola hepatica in sheep is addressed at a higher dose per kilogram than the cattle dose, reflecting pharmacokinetic differences between species. The importance of Haemonchus contortus in sheep cannot be overstated - this blood-feeding abomasal parasite is the most pathogenic nematode in small ruminants worldwide, and effective treatment of clinical haemonchosis is often a matter of animal survival.

Extra-label use of albendazole in goats is widespread and reflects the limited availability of anthelmintics specifically approved for caprine use. Goats metabolize benzimidazoles more rapidly than sheep or cattle, requiring higher doses to achieve equivalent drug exposure and therapeutic efficacy. Veterinary guidance is essential for establishing appropriate goat dosing protocols, as underdosing due to application of cattle or sheep label doses to goats is a recognized contributor to treatment failure and accelerated resistance development in goat parasite populations.

The labeled dose of albendazole for cattle is 10 milligrams per kilogram of body weight, equivalent to 4.54 milligrams per pound, administered as a single oral drench. Using the commercial 113.6 mg/mL suspension, this translates to approximately 8 milliliters per 100 kilograms (220 pounds) of body weight. Accurate dosing requires weighing animals or using a reliable estimation method, and the dose should be calculated based on the heaviest animal in each treatment group when individual weighing is not practical. Underdosing is the single most controllable risk factor for selecting resistant parasite genotypes and should be avoided through disciplined weight-based dosing rather than visual estimation.

The labeled dose for sheep is 7.5 milligrams per kilogram for nematode and tapeworm indications, administered as a single oral drench. For liver fluke treatment in sheep, a higher dose of 7.5 milligrams per kilogram is used, though some practitioners use elevated doses for fluke treatment based on efficacy data. The sheep dose is lower than the cattle dose on a per-kilogram basis because sheep have slower ruminal passage rates that result in longer drug exposure time and higher systemic drug levels per unit dose. This pharmacokinetic difference is specific to benzimidazoles and does not apply to other anthelmintic classes.

Goat dosing requires adjustment upward from sheep doses because goats metabolize benzimidazoles significantly faster than sheep, resulting in lower and shorter drug exposure at equivalent doses. The commonly recommended extra-label dose for goats is approximately 10 to 15 milligrams per kilogram, representing a substantial increase over the sheep label dose. Some parasitologists recommend doses at the higher end of this range for Haemonchus contortus treatment, particularly in herds with documented benzimidazole resistance. The veterinarian prescribing extra-label albendazole use in goats establishes the dose, frequency, and withdrawal time based on current pharmacokinetic data and the specific clinical situation.

Administration technique directly influences treatment efficacy. The oral suspension should be delivered over the back of the tongue using a properly calibrated drench gun to ensure the animal swallows the full dose rather than spitting it out. Animals should be adequately restrained to prevent head tossing during dosing, as aspiration of drench liquid into the trachea can cause aspiration pneumonia. The drench gun tip should be inserted along the side of the mouth and directed toward the back of the tongue, not forced straight back into the pharynx where it could damage tissue or deposit liquid directly into the airway. Each animal should be observed momentarily after dosing to confirm swallowing.

The timing of treatment relative to feeding status affects albendazole pharmacokinetics. Feeding animals before treatment slows ruminal passage and increases drug absorption, resulting in higher plasma drug levels and improved efficacy, particularly against dose-limiting parasites. In practical terms, holding animals off feed overnight and then providing hay before treatment, or simply treating animals that have been grazing normally, generally provides adequate ruminal fill. Treating fasted animals with empty rumens reduces drug exposure time and may compromise efficacy, especially at the lower end of the dosing range.

Albendazole carries the longest withdrawal times among commonly used livestock anthelmintics, a direct consequence of the drug's metabolic pathway and the persistence of its metabolites in edible tissues. The labeled slaughter withdrawal time for cattle is 27 days, meaning treated cattle must not be slaughtered for human consumption until a minimum of 27 days have elapsed since treatment. For sheep, the labeled slaughter withdrawal time is 7 days. These withdrawal periods reflect the time required for albendazole and its pharmacologically active metabolites - albendazole sulfoxide and albendazole sulfone - to decline below the established maximum residue limits in muscle, liver, kidney, and fat tissues.

The milk withdrawal for albendazole is absolute: the drug is not approved for use in lactating dairy cattle whose milk is destined for human consumption. The label statement prohibiting use in lactating dairy animals reflects the presence of drug residues in milk following treatment and the lack of an established milk withdrawal period. This restriction applies to all lactating dairy cattle regardless of production stage or milk destination. Dairy operations needing to treat lactating cows for liver flukes or nematodes must select alternative anthelmintics with established milk withdrawal periods, such as fenbendazole or eprinomectin, depending on the parasite target.

For goats used extra-label, withdrawal times must be established by the prescribing veterinarian and will exceed the labeled cattle or sheep withdrawal periods. The Food Animal Residue Avoidance Databank (FARAD) provides species-specific withdrawal time recommendations for extra-label drug use, and veterinarians prescribing albendazole for goats should consult FARAD for current guidance. Goat meat and milk enter human food supply chains, and residue avoidance is both a food safety obligation and a regulatory requirement under the Animal Medicinal Drug Use Clarification Act (AMDUCA), which governs extra-label drug use in food-producing animals.

Record keeping associated with albendazole treatment must document the date of treatment, the animals treated (individual identification or group identification), the dose administered, and the calculated withdrawal date for each treated group. These records serve as the producer's evidence of compliance with withdrawal requirements and should be maintained as part of the operation's standard animal health record system. For operations participating in quality assurance programs such as Beef Quality Assurance, proper documentation of treatment and withdrawal compliance is a core program requirement.

Export considerations add complexity to albendazole withdrawal management for operations selling livestock or meat into international markets. Maximum residue limits for albendazole metabolites vary between countries, and some export destinations impose longer withdrawal requirements than the domestic label specifies. Producers marketing cattle for export should verify the withdrawal requirements of the destination country and adjust their treatment-to-slaughter interval accordingly to prevent residue violations that could result in carcass condemnation and market access consequences.

Albendazole is teratogenic in cattle and sheep when administered during the first trimester of pregnancy, and this reproductive safety restriction is the most consequential management consideration associated with the drug's use. The label carries an explicit warning against use in female cattle during the first 45 days of pregnancy and in female sheep during the first 30 days of pregnancy. These restrictions are based on controlled studies demonstrating skeletal and soft tissue malformations in offspring exposed to albendazole during the critical period of organogenesis, when the developing fetus is most vulnerable to agents that disrupt cell division and differentiation.

The teratogenic mechanism relates directly to albendazole's mode of action against parasites. Beta-tubulin, the molecular target of benzimidazole binding, is essential for microtubule formation in all dividing cells, including the rapidly proliferating cells of the developing embryo. During organogenesis, the precise assembly and disassembly of microtubules directs cell migration, tissue folding, limb bud development, and organ formation. Disruption of microtubule function during these processes produces structural malformations whose nature depends on the specific developmental stage at which exposure occurs. The types of malformations reported in albendazole-exposed livestock embryos include skeletal defects, craniofacial abnormalities, and limb deformities consistent with disrupted morphogenetic processes.

Practical management of albendazole's teratogenic risk requires precise knowledge of breeding dates for all females in the treatment group. In operations using defined breeding seasons with known bull turnout or artificial insemination dates, the first 45 days (cattle) or 30 days (sheep) following breeding can be identified and treatment avoided during this window. For operations using continuous year-round breeding or where breeding dates are uncertain, albendazole should not be used in any female of breeding age unless pregnancy during the critical window can be definitively excluded. This often means substituting fenbendazole, which does not carry a teratogenic warning at labeled doses, for routine deworming of breeding females.

The distinction between albendazole and fenbendazole regarding reproductive safety is important for producers to understand. Both drugs are benzimidazoles that share the same mechanism of action, but fenbendazole is labeled as safe for use in pregnant animals at recommended doses, while albendazole is explicitly contraindicated in early pregnancy. This difference is attributed to pharmacokinetic factors, including the specific metabolite profiles and embryonic exposure levels achieved by each drug, rather than a fundamental difference in mechanism. Producers sometimes assume that all benzimidazoles carry the same pregnancy restrictions, which can lead to unnecessary avoidance of fenbendazole in pregnant animals, or conversely, to dangerous assumption that albendazole is safe because fenbendazole is.

Bulls and rams can be treated with albendazole at any time, as there is no evidence of adverse effects on male fertility or sperm quality at labeled doses. The teratogenic concern is limited to direct embryonic exposure through the treated dam's systemic circulation during the period of organogenesis. Male animals do not transmit drug or metabolites to females in quantities relevant to teratogenic risk. This means that albendazole can be used freely in males regardless of their breeding status, simplifying treatment decisions for operations that need flukicidal activity in breeding bulls or rams.

Albendazole is well tolerated at labeled doses in cattle, sheep, and goats, and significant adverse reactions in non-pregnant animals are uncommon. The benzimidazole class has a wide therapeutic index, meaning the ratio between the effective dose and the dose that produces toxicity is large, providing a substantial margin of safety for properly dosed animals. Most animals show no observable response to treatment beyond the intended antiparasitic effect. The favorable safety profile of benzimidazoles relative to other anthelmintic classes is one reason they have remained in widespread use for decades.

Gastrointestinal effects including transient soft feces, mild diarrhea, or brief reduction in feed intake have been reported occasionally following albendazole administration, though it is difficult to distinguish direct drug effects from the consequences of parasite die-off within the gastrointestinal tract. The death and disintegration of large numbers of gastrointestinal nematodes following effective treatment releases inflammatory mediators and antigenic material that can cause local mucosal irritation and transient changes in gut motility and fluid balance. These effects are generally self-limiting and resolve within 24 to 48 hours without intervention.

Overdose toxicity with albendazole produces dose-dependent signs that reflect the drug's disruption of rapidly dividing cell populations in the host. At doses substantially exceeding the labeled recommendation - typically three to five times the therapeutic dose or higher - albendazole can cause bone marrow suppression, manifesting as leukopenia, anemia, and thrombocytopenia. Hepatotoxicity evidenced by elevated liver enzymes and clinical jaundice has been reported at toxic doses. Gastrointestinal erosion and ulceration may also occur. These toxic effects are relevant primarily in accidental overdose scenarios or in situations where dosing calculations are grossly incorrect. At labeled doses, bone marrow and hepatic toxicity are not expected.

Hypersensitivity reactions to albendazole itself are rare, but host reactions to the rapid die-off of certain parasite species can produce clinical signs that mimic drug hypersensitivity. Treatment of heavy Fasciola hepatica infections can cause acute hepatic inflammation as dying flukes release tissue-damaging enzymes and provoke an intense local inflammatory response within the bile ducts and liver parenchyma. Clinical signs may include fever, depression, abdominal pain, and in severe cases hepatic failure. This reaction reflects the pathological consequences of parasite death within the liver rather than a direct drug toxicity, and it is more likely when treatment is directed at heavy mature fluke burdens that have already caused significant hepatic pathology.

Albendazole has few clinically significant drug interactions in livestock species, though concurrent use with other benzimidazoles should be avoided as it provides no additional efficacy benefit while increasing the risk of dose-dependent toxicity. Combination of albendazole with other anthelmintic classes - macrocyclic lactones (ivermectin, moxidectin) or nicotinic agonists (levamisole) - is an accepted resistance management practice that targets resistant parasite subpopulations with drugs having different mechanisms of action. Combination treatment is increasingly recommended by parasitologists as a strategy to slow the development and spread of multi-drug-resistant nematode populations, and albendazole is commonly used as the benzimidazole component in these combination protocols.

Benzimidazole resistance in gastrointestinal nematodes is widespread and represents the most mature and geographically extensive form of anthelmintic resistance in livestock parasites globally. Resistance to benzimidazoles has been documented in virtually every major nematode species affecting cattle, sheep, and goats, with the highest prevalence in small ruminant parasites, particularly Haemonchus contortus and Teladorsagia circumcincta. The molecular basis of benzimidazole resistance is well characterized and involves single nucleotide polymorphisms in the beta-tubulin gene at specific codon positions (primarily codons 167, 198, and 200) that reduce the binding affinity of benzimidazole drugs for their target molecule. These mutations are heritable, and selection pressure from repeated benzimidazole use drives the frequency of resistant alleles upward in parasite populations over time.

Fecal egg count reduction testing (FECRT) is the primary field method for detecting anthelmintic resistance and should be performed periodically to verify that albendazole remains effective in a given operation's parasite population. The procedure involves collecting fecal samples from treated animals before treatment and again ten to fourteen days after treatment, with the percentage reduction in fecal egg count indicating treatment efficacy. A reduction of less than 95 percent in cattle or less than 95 percent in sheep (with the lower 95 percent confidence interval below 90 percent) is considered evidence of resistance. Operations that detect benzimidazole resistance should modify their deworming program in consultation with a veterinary parasitologist to preserve the efficacy of remaining effective drug classes.

Refugia-based management is the contemporary paradigm for sustainable anthelmintic use and directly influences how albendazole should be deployed within a deworming program. The principle of refugia holds that maintaining a population of drug-susceptible parasites in the environment - worms that have not been exposed to treatment and therefore have not been selected for resistance - dilutes the proportion of resistant genotypes in the overall parasite population. Practical applications include treating only animals that need treatment based on clinical indicators or fecal egg counts (targeted selective treatment), leaving a proportion of animals untreated to maintain refugia, avoiding treatment immediately before or after moving animals to clean pasture where only resistant survivors would establish the new pasture population, and timing treatments strategically rather than calendar-based dosing.

The role of albendazole in modern integrated parasite management programs is defined by its unique flukicidal spectrum, its position within the benzimidazole resistance landscape, and its reproductive safety constraints. Operations in fluke-endemic areas retain albendazole as an essential tool for fluke control in non-pregnant animals, while relying on fenbendazole or other anthelmintics for routine nematode treatment in breeding females. Operations outside fluke areas may find fenbendazole preferable for routine use given its equivalent nematode spectrum without the pregnancy restriction. In either case, preservation of benzimidazole efficacy through responsible use - accurate dosing, resistance monitoring, refugia management, and combination treatment strategies - serves the long-term interests of the operation and the livestock industry.

Albendazole oral suspension should be stored at controlled room temperature between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), protected from freezing and excessive heat. The product should be kept in its original container with the cap tightly secured between uses. Exposure to extreme temperatures can alter the physical properties of the suspension, affecting both the uniformity of drug distribution within the vehicle and the chemical stability of the active ingredient. Frozen product should be discarded rather than thawed and used, as freeze-thaw cycles can cause irreversible changes in particle size distribution that affect dosing accuracy and bioavailability.

Thorough shaking before each use is essential for accurate dosing. Albendazole is formulated as a suspension rather than a solution, meaning the active ingredient exists as undissolved particles distributed throughout the liquid vehicle. These particles settle during storage, creating a concentration gradient with drug-depleted liquid at the top of the container and a concentrated sediment at the bottom. Without vigorous shaking to resuspend the particles uniformly, the first doses drawn from the container will deliver substantially less drug than intended, while doses drawn from the settled sediment will deliver substantially more. Both scenarios compromise treatment outcomes - underdosing promotes resistance selection, while overdosing wastes product and increases the risk of adverse effects.

Drench gun calibration and maintenance affect dosing accuracy at the point of delivery. The drench gun should be calibrated before each treatment session by verifying that the delivered volume matches the gun setting, using a graduated cylinder or syringe to measure the actual volume dispensed per stroke. Worn O-rings, cracked barrels, and sticky plungers in drench guns cause inconsistent delivery that introduces dosing variation across the treatment group. Regular inspection and maintenance of dosing equipment is a simple quality control step that prevents systematic under- or overdosing.

Human safety precautions during albendazole handling reflect the drug's known teratogenic properties. Personnel who may be pregnant or who are of childbearing age and not using effective contraception should avoid handling the product. Skin contact should be minimized through glove use, and hands should be washed thoroughly after handling. Accidental ingestion or significant skin exposure should be reported to a physician. Spilled product should be cleaned up promptly and disposed of according to local waste regulations. While the risk from incidental occupational exposure is low, the severity of the potential teratogenic consequence warrants consistent adherence to basic handling precautions.

Disposal of unused or expired albendazole should follow environmental regulations applicable to pharmaceutical waste. Benzimidazole anthelmintics are toxic to certain aquatic invertebrates, and improper disposal through dumping or discharge into waterways can cause environmental harm. Empty containers should be rinsed and disposed of according to label directions. Expired product should not be used, as chemical degradation may reduce efficacy and alter the safety profile. Most agricultural waste disposal programs accept expired veterinary pharmaceuticals, and producers should utilize these services rather than disposing of product through improvised methods.

Cattle represent the primary labeled species for albendazole use, and the drug's role in cattle parasite management is shaped by its dual activity against gastrointestinal nematodes and liver flukes. In cow-calf operations, strategic treatment timing aligns with known periods of parasite risk: treatment at housing in fall targets acquired nematode burdens and liver flukes before the winter feeding period, while spring treatment addresses inhibited Ostertagia larvae that emerge from the abomasal mucosa as temperatures rise. Stocker and backgrounder operations often treat cattle on arrival to reduce parasite burdens acquired on previous pastures and to prevent clinical parasitism during the high-growth-rate feeding period. Feedlot cattle are typically treated on arrival processing as part of a standardized health protocol.

The management of Fasciola hepatica in cattle requires understanding of the fluke's life cycle and the seasonal timing of infection risk. Cattle acquire fluke infection by ingesting metacercariae encysted on vegetation in wet, poorly drained pasture areas harboring the Lymnaea snail intermediate host. Ingested metacercariae excyst in the duodenum, penetrate the intestinal wall, migrate through the peritoneal cavity to the liver, and spend several weeks burrowing through liver parenchyma before reaching the bile ducts where they mature into egg-producing adults. Albendazole is most effective against adult flukes in the bile ducts and has limited activity against immature flukes still migrating through the liver. Treatment timing should target the period when the majority of the fluke population has reached the bile duct stage, typically twelve or more weeks after the end of the grazing season in seasonal transmission areas.

Sheep parasitology places unique demands on anthelmintic selection that influence how albendazole is used in ovine flocks. Haemonchus contortus, the barber pole worm, is the most pathogenic and economically important nematode in sheep worldwide, causing acute blood-loss anemia that can kill lambs and ewes rapidly during periods of high pasture contamination. Benzimidazole resistance in H. contortus is extremely common in sheep flocks, and fecal egg count reduction testing should be performed before relying on albendazole or any benzimidazole for Haemonchus control. In flocks where benzimidazole resistance has been confirmed, albendazole retains value only as a component of combination treatment protocols rather than as a standalone dewormer.

Goat parasitology is dominated by the same species that affect sheep, but the pharmacokinetic differences between goats and sheep fundamentally alter dosing requirements for albendazole. Goats have faster hepatic metabolism of benzimidazoles, higher volumes of distribution, and more rapid drug clearance than sheep, resulting in lower peak plasma concentrations and shorter duration of drug exposure at equivalent doses. These pharmacokinetic disadvantages mean that goats treated at sheep label doses receive subtherapeutic drug exposure, leading to poor efficacy and accelerated resistance selection. The practical consequence is that goat producers must work with their veterinarian to establish appropriate extra-label doses, typically 50 to 100 percent above the sheep label dose, and must observe extended withdrawal times established by the prescribing veterinarian.

Swine, poultry, and other farm animal species are not included in the albendazole label and their treatment with this drug is uncommon. While albendazole has broad-spectrum activity against nematodes that could theoretically benefit other livestock species, the availability of species-specific anthelmintics with established doses, safety data, and withdrawal times for these species makes extra-label albendazole use unnecessary in most situations. Camelid species (llamas and alpacas) are occasionally treated extra-label with albendazole under veterinary guidance, particularly for liver fluke infections in fluke-endemic regions where these animals share pasture with cattle and sheep.